By Lynda Williams, medwireNews Reporter
medwireNews: The neurokinin-targeted agent elinzanetant significantly improves vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer, research indicates.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit: © yacobchuk / Getty Images / iStock
